Core Insights - TransCode Therapeutics, Inc. has initiated Cohort 3 of its Phase 1 clinical trial for TTX-MC138, with three patients enrolled and dosed, following unanimous approval from the Safety Review Committee based on prior cohorts' safety and pharmacokinetic data [1][2] - The trial has shown no significant safety or dose-limiting toxicities across the nine patients in the first two cohorts, with ongoing analyses indicating a pharmacokinetic and pharmacodynamic profile consistent with preclinical results [2][7] - TTX-MC138 is designed to inhibit microRNA-10b, which is implicated in the progression of metastatic cancers, and has demonstrated pharmacodynamic activity in previous trials, suggesting a broad therapeutic window [3][6] Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on RNA therapeutics for treating metastatic diseases, utilizing its proprietary TTX nanoparticle platform [6] - The lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis [6] - The Phase 1 clinical trial is structured as a multicenter, open-label, dose-escalation and dose-expansion study aimed at evaluating the safety and tolerability of TTX-MC138 in various metastatic solid cancers [4]
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial